vedotin-话题@MedSci - 梅斯（MedSci）

#vedotin#

36篇内容 | 1689人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1527055, encodeId=6cb3152e055e0, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, objectType=article, longId=734317, objectId=5093e34317c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5093e34317c1, replyNumber=0, likeNumber=122, createdTime=2022-08-05, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5093e34317c1, moduleTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5093e34317c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527054, encodeId=8fd7152e05429, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=62, createdTime=2022-04-20, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527053, encodeId=a515152e053cb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, objectType=article, longId=295542, objectId=e92329554273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92329554273, replyNumber=0, likeNumber=87, createdTime=2022-02-14, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92329554273, moduleTitle=NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e92329554273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527052, encodeId=cd88152e0528a, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, objectType=article, longId=213718, objectId=fd62213e1849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd62213e1849, replyNumber=0, likeNumber=83, createdTime=2021-07-06, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd62213e1849, moduleTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fd62213e1849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527051, encodeId=4ee2152e051d1, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=107, createdTime=2021-05-16, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527050, encodeId=a119152e050f5, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, objectType=article, longId=209902, objectId=2b4f20990217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b4f20990217, replyNumber=0, likeNumber=64, createdTime=2021-04-14, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b4f20990217, moduleTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2b4f20990217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527049, encodeId=dde2152e049a4, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, objectType=article, longId=209110, objectId=46be20911056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46be20911056, replyNumber=0, likeNumber=101, createdTime=2021-03-29, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46be20911056, moduleTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46be20911056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527048, encodeId=cadf152e04857, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=64, createdTime=2021-03-29, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527047, encodeId=8302152e04731, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, objectType=article, longId=207205, objectId=96bf20e20583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bf20e20583, replyNumber=0, likeNumber=65, createdTime=2021-02-18, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bf20e20583, moduleTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=96bf20e20583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527046, encodeId=874e152e046d7, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, objectType=article, longId=207094, objectId=a84a20e094e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a84a20e094e5, replyNumber=0, likeNumber=132, createdTime=2021-02-15, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a84a20e094e5, moduleTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a84a20e094e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527045, encodeId=9e51152e0459b, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, objectType=article, longId=201251, objectId=a8de201251f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de201251f5, replyNumber=0, likeNumber=154, createdTime=2020-09-28, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de201251f5, moduleTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a8de201251f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527044, encodeId=d191152e044a5, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, objectType=article, longId=199963, objectId=5ce5199963fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce5199963fc, replyNumber=0, likeNumber=68, createdTime=2020-08-29, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce5199963fc, moduleTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ce5199963fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527043, encodeId=bc0c152e043d7, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=70, createdTime=2020-07-02, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=72, createdTime=2020-05-18, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527041, encodeId=5e0f152e041a7, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, objectType=article, longId=188519, objectId=cccf188519dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cccf188519dd, replyNumber=0, likeNumber=74, createdTime=2020-02-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cccf188519dd, moduleTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cccf188519dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=125, createdTime=2019-11-23, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527039, encodeId=247c152e0393f, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效, objectType=article, longId=179923, objectId=61081e992379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61081e992379, replyNumber=0, likeNumber=99, createdTime=2019-09-25, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61081e992379, moduleTitle=马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=61081e992379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527038, encodeId=52f3152e03803, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=98, createdTime=2019-09-19, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527037, encodeId=6937152e037dd, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, objectType=article, longId=174409, objectId=3ff21e440907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff21e440907, replyNumber=0, likeNumber=144, createdTime=2019-06-30, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff21e440907, moduleTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3ff21e440907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527036, encodeId=5d33152e03667, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, objectTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, objectType=article, longId=168996, objectId=019516899631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019516899631, replyNumber=0, likeNumber=82, createdTime=2019-06-24, rootId=0, userName=jiangfeng5071, userId=620c11794019, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019516899631, moduleTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=019516899631)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

vedotin

2020-05-29

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法

2022-08-05

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌

2022-04-20

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

NEJM：采用Polatuzumab Vedotin治疗初治弥漫性大B细胞淋巴瘤

2022-02-14

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤

2021-07-06

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2021-05-16

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效

2021-04-14

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）

2021-03-29

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）

2021-03-29

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）

2021-02-18

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用

2021-02-15

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”

2020-09-28

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展

2020-08-29

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2020-07-02

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-05-18

heli0118 (审核中...)

前往app查看评论内容

#vedotin#

PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定

2020-02-22

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-23

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效

2019-09-25

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2019-09-19

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔

2019-06-30

jiangfeng5071 (审核中...)

前往app查看评论内容

#vedotin#

Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破

2019-06-24

科室
- - 订阅+
  - 更多科室
工具
服务